Vibra Healthcare, MindMaze Collaborate on Digital Health Solutions

Vibra Healthcare is partnering with the neurotechnology company MindMaze to provide digital neurotherapeutic tools for people with neurological disorders both in the clinic and at home.

The initiative will start with patients at select Vibra hospitals in Kentucky and California.

MindMaze’s digital health solutions aim to help people with Parkinson’s disease, stroke, traumatic brain injury, or spinal cord injury regain function through digitally-enabled evaluations and behavioral training of motor, cognitive, and cardiovascular systems.

Recommended Reading

Two people are shown from behind with their arms wrapped around each other.

The artificial intelligence (AI)-powered technology platform — including tools such as MindPod, TOAP Run, and Brain Vitals — can intervene with and assess neurological disorders, and monitor and gauge patient function during long-term disease management.

“Vibra is committed to delivering the best possible care for our patients and the best value for our customers,” Brad Hollinger, Vibra’s founder, chairman, and CEO, said in a press release.

“We strongly believe that innovative technology in AI is the pioneering path forward to dramatically improve patient outcomes in the most cost-effective way,” Hollinger added. “MindMaze has impressed our team not just with the power of their technological capabilities, but also with their experience in deploying real-world care pathways for patients with stroke and other neurological conditions in countries around the world.”

Nearly 100 million U.S. residents have a neurological disorder that can worsen over time. Such disorders burden the healthcare system and account for almost half of the overall U.S. healthcare burden, according to the press release.

Switzerland-based MindMaze believes a multimodal technological approach is needed to address the growing challenges. While behavioral, cognitive, and motor interventions usually help patients with neurological conditions, the use of technology could effectively lead to wider digital health solutions that improve patient outcomes.

Research has shown that high-dosage, high-intensity training can result in improved outcomes in neurological conditions that are traditionally difficult to treat.

‘Redefining neuro recovery’

Tej Tadi, MindMaze’s founder, chairman, and CEO, said the company “is committed to redefining neuro recovery across the continuum of care through the development [of] evidence-driven solutions for patients with serious neurological conditions.”

“We are focused on providing clinicians with powerful, digitally enabled, cutting-edge tools, while also empowering patients and their families with easy-to-use, engaging, and accessible solutions,” Tadi said.

Through the partnership, which kicks off what is hoped will be an expansive roll-out of MindMaze solutions, clinicians will be able to provide patients with in-clinic and at-home interventions “at dosage and intensity levels that are orders of magnitude higher than the current standard of care,” the release stated.

The aim is to develop a universal platform to improve patient care across a variety of environments: in-patient, post-acute, community sub-acute, and at-home.

The collaboration is expected to facilitate a “substantial” boost in the treatment and training of Vibra patients, as well as smooth and organized care transitions for Vibra Healthcare System patients. The system operates and manages some 90 specialty hospitals and transitional care locations in 19 states.

“Our facilities have consistently ranked among the top-rated hospitals and rehabilitation facilities in the country, and we are always looking for ways to improve upon our incredibly high standards,” Hollinger said.

Tadi added: “In Vibra we have found a world-class partner with both the commitment and true capability to deliver a step change in brain health as well as meaningful improvements in patient outcomes.”

Last month, MindMaze initiated a collaboration with Mount Sinai Health System to speed patient access to its novel neurotherapeutic program.



Leave a Reply

Your email address will not be published. Required fields are marked *